Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06888921 · ClinicalTrials.gov registry record · Phase 1

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

A Phase 1 study of Ovarian Cancer and Ovarian Cancer Recurrent, sponsored by Compugen.

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
20
Study locations

NCT06888921: Recruiting Phase 1 study of Ovarian Cancer and Ovarian Cancer Recurrent, sponsored by Compugen.

NCT06888921 is a Phase 1 study of Ovarian Cancer and Ovarian Cancer Recurrent that is actively recruiting participants, run by Compugen. The registered enrollment target is 60 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06888921, a Phase 1 study of Ovarian Cancer and Ovarian Cancer Recurrent, is actively recruiting participants, sponsored by Compugen.

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,

Primary Outcome

Progression free survival in COM701-treated participants compared to placebo-treated participants

Conditions Studied

Ovarian Cancer Ovarian Cancer Recurrent

Interventions

  • DRUG Normal Saline
  • DRUG COM701

Study Locations (20)

Other

  • Centre Oscar Lambret - Lille
  • Institut Paoli-Calmettes - Marseille
  • Hospices Civils de Lyon- Centre Hospitalier Lyon Sud - Pierre-Bénite
  • Centre Eugene Marquis - Rennes

Illinois

  • The University of Chicago Medical Center - Chicago
  • Northwestern Memorial Hospital - Warrenville

New York

  • Memorial Sloan Kettering Cancer Center- Main Campus - New York
  • University of Rochester Medical Center - Rochester

France

  • Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz - Besançon
  • Oncopole Claudius Regaud - Toulouse

Georgia

  • Georgia Cancer Center at Augusta University - Augusta

Massachusetts

  • Massachusetts General Hospital - Boston

Michigan

  • Corewell Health - Grand Rapids

North Carolina

  • Levine Cancer Institute - Charlotte

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-07-21
Est. Completion 2027-03
Phase Phase 1
Compugen

5 total trials

What NCT06888921 shows while recruiting

NCT06888921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower).

The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.

NCT06888921 names 20 study sites across 14 states, led by Other, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT06888921 about?

NCT06888921 is a clinical study titled "A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer". The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, w...

What is the current status of trial NCT06888921?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-07-21. Estimated completion is 2027-03.

What conditions does trial NCT06888921 study?

This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Cancer Recurrent.

What interventions are being tested in trial NCT06888921?

The interventions under investigation include: Normal Saline (DRUG), COM701 (DRUG).

Who is sponsoring clinical trial NCT06888921?

This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06888921 being conducted?

This trial has 20 study locations across Georgia, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06888921's enrollment target sits among peer trials

60 193rd of 322 higher than 123 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06888921

Source: ClinicalTrials.gov NCT06888921, the US trial registry maintained by the National Library of Medicine. NCT06888921 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.